- Home
- ZGN vs VRDN Comparison
ZGN vs VRDN Comparison
Compare ZGN & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZGN
- VRDN
- Stock Information
- Founded
- ZGN 1910
- VRDN 2006
- Country
- ZGN Italy
- VRDN United States
- Employees
- ZGN N/A
- VRDN N/A
- Industry
- ZGN Apparel
- VRDN Medical Specialities
- Sector
- ZGN Consumer Discretionary
- VRDN Health Care
- Exchange
- ZGN Nasdaq
- VRDN Nasdaq
- Market Cap
- ZGN 1.9B
- VRDN 1.6B
- IPO Year
- ZGN N/A
- VRDN N/A
- Fundamental
- Price
- ZGN $7.67
- VRDN $13.44
- Analyst Decision
- ZGN Buy
- VRDN Buy
- Analyst Count
- ZGN 2
- VRDN 12
- Target Price
- ZGN $8.05
- VRDN $36.44
- AVG Volume (30 Days)
- ZGN 1.0M
- VRDN 1.1M
- Earning Date
- ZGN 03-27-2025
- VRDN 05-07-2025
- Dividend Yield
- ZGN 1.67%
- VRDN N/A
- EPS Growth
- ZGN N/A
- VRDN N/A
- EPS
- ZGN 0.31
- VRDN N/A
- Revenue
- ZGN $2,015,371,157.00
- VRDN $302,000.00
- Revenue This Year
- ZGN $2.59
- VRDN N/A
- Revenue Next Year
- ZGN $5.41
- VRDN $20,553.29
- P/E Ratio
- ZGN $24.79
- VRDN N/A
- Revenue Growth
- ZGN 2.21
- VRDN N/A
- 52 Week Low
- ZGN $6.05
- VRDN $9.90
- 52 Week High
- ZGN $13.36
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- ZGN 58.43
- VRDN 50.08
- Support Level
- ZGN $6.82
- VRDN $9.90
- Resistance Level
- ZGN $7.15
- VRDN $14.61
- Average True Range (ATR)
- ZGN 0.41
- VRDN 1.12
- MACD
- ZGN 0.13
- VRDN 0.29
- Stochastic Oscillator
- ZGN 95.12
- VRDN 77.81
About ZGN Ermenegildo Zegna N.V.
Ermenegildo Zegna NV designs creates, and distributes luxury menswear and accessories under the Zegna brand, as well as womenswear, menswear, and accessories under the Thom Browne brand. The company operates in three segments: the Zegna segment (comprising three product lines: Zegna Branded Products, Textile, and Third Party Brands); the Thom Browne segment, and the Tom Ford Fashion segment. The company generates the majority of its revenue from the Zegna segment.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.